In a 68-patient Phase 2 clinical trial , Ocular Therapeutix's (NASDAQ: OCUL ) Sustained Release Dexamethasone (OTX-DP) achieves one efficacy endpoint of statistically significant lower ocular itching and conjunctival redness scores versus placebo on days 14, 28 and 42 after insertion of the punc
canaliculus הגייה עם משמעויות, מילים נרדפות, הפכים, תרגומים, משפטים ועוד